CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14,965 enrolled
Drug / intervention
Lansoprazoledrug
Likely dose
Lansoprazole 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01990339
NCT01990339N/ACompleted
CompareCT.gov

Takepron Specified Drug-use Survey "Gastroesophageal Reflux Disease With Dyspepsia Symptoms"

Takeda·observational·Posted Nov 21, 2013·Updated Sep 27, 2016

In Brief

An observational study evaluating Lansoprazole for Gastroesophageal Reflux Disease With Dyspepsia Symptoms. Completed, enrolled 14,965 participants.

Detailed Summary

To evaluate the efficacy of 4-week lansoprazole (Takepron) therapy for subjective symptomatic improvement in gastroesophageal reflux disease patients with dyspepsia symptoms

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease With Dyspepsia Symptoms
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 21, 2013
Enrollment StartDec 1, 2008
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.6 years ago

Interventions

Lansoprazoledrug

• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks. For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. • Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.